Abstract: Tubular prostheses are provided for use in airways, upper digestive, and urinary tracts. Each of these uses has its own specific sets of biological specifications, based on what it must contain and exclude and the physical and chemical pressures and stresses to which it is subjected. The prostheses may be made from allogeneic cells. Thus they can be manufactured and stored prior to an individual's personal need arising.

Abstract: A method of detecting sub-surface voids in a sample comprises positioning a probe adjacent to a first point on the sample, emitting an ultrasonic wave from the probe towards the sample, moving the probe towards the sample, measuring a shear force amplitude of a reflection of the ultrasonic wave at the probe as the probe moves towards the sample, creating an approach curve by plotting the measured shear force amplitude of the reflection of the ultrasonic wave as a function of a distance between the probe and the sample, and determining whether a sub-surface void exists at the first point on the sample based on a slope of the approach curve.

Abstract: Provided herein are compositions comprising: a scaffold polymer having one or more acryloyl groups or one or more methacryloyl groups; optionally a porogen and a crosslinking agent, compositions that upon crosslinking form a hydrogel for use in cell encapsulation and methods for immunocytochemistry of encapsulated cells. Scaffold polymers used are selected from: Poly(ethylene glycol) diacrylate (PEGDA); Poly(ethylene glycol) dimethylacrylate (PEGDMA); Poly(ethylene glycol) methyl ether acrylate (PEGMEA); Poly(ethylene glycol) methacrylate (PEGMA); and Poly(ethylene glycol) methyl ether methacrylate (PEGMEMA), and porogens selected from: Poly(ethylene glycol) (PEG); Chitosan; Agarose; Dextran; Hyaluronic acid; Poly(methyl methacrylate) (PMMA); Cellulose and derivatives thereof; Gelatin and derivatives thereof; and Acrylamide and derivatives thereof. The invention also provides, at least in part, compositions for forming a porous hydrogel around a cell suitable for immunostaining of cells within the hydrogel.

Abstract: For wireless communication method, a to-be-transmitting signal is divided into (n+1) packets using a key pre-agreed to by a transmitter and a receiver, where n is a positive integer. The to-be-transmitted signal comprising a regular signal and a tag signal, said tag signal forming an authentication signal. When the difference between received amplitude values of the regular signal and tag signal fail to meet a first pre-determined requirement, a first power parameter adjustment factor is determined for the n packets preceding an (n+1)th packet and a second power parameter adjustment factor is determined for the (n+1)th packet, as well as an energy-limited condition of the to-be-transmitted signal power. The transmitted power of the respective (n+1) packets is then adjusted according to the corresponding power parameter adjustment factor before the to-be-transmitted signal is transmitted.

Abstract: Disclosed herein are embodiments of a donor compound that releases H2S by reacting with a reactive compound. The donor compound embodiments described herein can be used to deliver H2S to a subject or a sample and further can be used to administer therapeutic agents. The donor compound embodiments also can facilitate bioconjugation. Methods of making and using the donor compound embodiments also are disclosed.

Abstract: IL-11R? antibodies are disclosed. Also disclosed are compositions comprising the IL-11R? antibodies, and methods using the IL-11R? antibodies.

Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma.

Abstract: A method for use in optical imaging, a system for using in optical imaging, and an optical system includes a controller arranged to determine an intermediate position of a sample upon a detection of a completion of a first movement of the sample, and to derive an optimal position associated with the intermediate position; a manipulator arranged to move the sample from the intermediate position to the optimal position with a second movement; wherein the sample is arranged to be observed using an optical instrument in the optimal position.

Abstract: The present invention relates to a surface source blackbody. The plane source blackbody comprises a panel, and a plurality of carbon nanotubes. The panel comprises a first surface and a second surface opposite to the first surface. A carbon nanotube array is located on the first surface of the panel. The carbon nanotube array comprises a plurality of carbon nanotubes. The plurality of carbon nanotubes are substantially perpendicular to the first surface of the panel. The carbon nanotube array has a high emissivity, so the plane source blackbody using the carbon nanotube array as a surface material has a high effective emissivity.

Abstract: Disclosed herein are a video decoding method and apparatus and a video encoding method and apparatus. In video encoding and decoding, inter-prediction information for a target block may be derived, and inter prediction for a target block may be performed using the derived inter-prediction information. Combined inter-prediction information may be performed by combining multiple pieces of inter-prediction information, and the combined inter-prediction information may be added as a candidate to a list used for inter prediction. One of candidates in the list may be selected for inter prediction for the target block, and inter prediction using the selected candidate may be performed.

Abstract: A method of CMP includes providing a slurry solution including ?1 per-compound oxidizer in a concentration between 0.01 M and 2 M with a pH from 2 to 5 or 8 to 11, and ?1 buffering agent which provides a buffering ratio ?1.5 that compares an amount of a strong acid needed to reduce the pH from 9.0 to 3.0 as compared to an amount of strong acid to change the pH from 9.0 to 3.0 without the buffering agent. The slurry solution is exclusive any hard slurry particles or has only soft slurry particles that have throughout a Vickers hardness <300 Kg/mm2 or Mohs Hardness <4. The slurry solution is dispensed on a hard surface having a Vickers hardness >1,000 kg/mm2 is pressed by a polishing pad with the slurry solution in between while rotating the polishing pad relative to the hard surface.

Abstract: Cancer treatment is provided, by irradiating an individual with a localized, high single dose or short course of doses at a primary tumor site; collecting T cells from the individual after a period of time sufficient activation of an anti-tumor response; treating the individual with an effective dose of dose of chemotherapy; and reintroducing the T cell population back to the individual.

Abstract: A holographic display system includes a light source that emits coherent light; a lateral displacement beam splitter that optically receives the coherent light and generates first reference light and second reference light; a first spatial light modulator (SLM) and a second SLM that optically receive the first reference light and the second reference light respectively, and construct first phase-only function (POF) light and second POF light respectively; a first beam splitter and a second beam splitter that optically receive the first POF light and the second POF light respectively, and generate first split light and second split light respectively; and a plurality of polarizers disposed between the first SLM and the first beam splitter, and between the second SLM and the second beam splitter, respectively.

Abstract: A controllable preparation method for a plasmonic nanonail structure is provided. A size of a nanomaterial can be controlled at sub-wavelength. The nanomaterial has good localized surface plasmon resonance effect, and the optical, electrical and mechanical properties of the nanometer material all can be regulated. The plasmonic nanonail is composed of two parts, i.e., a silver nanorod, a gold nanorod or a silver-gold-silver alloy nanorod and an approximate equilateral triangular nano-silver plate growing on the nanorod. A length of the nanorod is controlled within 20-30 nanometers, a diameter of the nanorod is controlled within 10-200 nanometers, a side length of the triangular nano-silver plate is controlled within 20 nanometers to 2 microns, and a size of the triangular plate is less than or equal to the length of the nanorod.

Abstract: Disclosed herein are a glaucoma diagnosis method using a fundus image and an apparatus for the same. The glaucoma diagnosis method includes performing data amplification of generating multiple transformed images for an original fundus image based on a preprocessed image of the original fundus image, allowing multiple individual learning models of different types to be learned based on the multiple transformed images and generating a glaucoma determination model based on respective outputs of the learned multiple individual learning models, and diagnosing a class of glaucoma for the original fundus image based on the glaucoma determination model.

Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or bispecific comprising said TCR, said cell, said clone or said vector; use of said TCR or said cell or said clone or said vector or said pharmaceutical composition or bispecific to treat cancer; and a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition or bispecific comprising said TCR.

Abstract: The present subject matter provides processes and kits for identifying the presence of waste water or human-derived pathogens, particularly those associated with the presence of human fecal matter, in surface or subsurface water sources.

Abstract: Compounds that inhibit p38? MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

Abstract: In a method of electrospinning nanofibres, a non-conductive laminate fibre collection structure (22) is placed on the surface of a conductive collector (18, FIG. 1). The laminate structure has a base layer (26) proximal to the collector and a fibre support layer (24). A pair of spaced first apertures (32) and a second aperture (34) located between them are defined through the fibre support layer (24). A pair of spaced third apertures (38) are defined through the base layer (26), each third aperture being aligned with one of the first apertures to define an opening (40) through the laminate structure. During electro spinning, the fibre is attracted to one of the openings (40) where it forms a bridge across the respective first aperture (32). A charge in the collected fibre builds up until the fibre is repelled and it moves to the nearest lowest potential region which is the second opening on the opposite side of the second aperture (34).

Abstract: The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis.